Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

Nephrology Dialysis Transplantation(2022)10.1093/ndt/gfac198Source: DataRank Database

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE) is a research paper published in Nephrology Dialysis Transplantation (2022). On theSindex it has a DataRank of 0. It has been cited 160 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access160 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 18.05)OA: hybridTopics (62)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Amy K. Mottl ORCID,George L. Bakris ORCID,Hiddo J.L. Heerspink ORCID,Johannes F.E. Mann ORCID,Janet B. McGill ORCID

Live enrichment

PubMed:35700142 PMC:PMC10064838 OpenAlex:https://openalex.org/W4282925091

Canadian Institutes of Health Research

Grant: unidentified

unidentified

Bayer AG

FWCI

18.05

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc

journalhttps://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfac198/44909708/gfac198.pdf

publisherhttps://academic.oup.com/ndt/advance-article-pdf/doi/10.1093/ndt/gfac198/44909708/gfac198.pdf

publisherhttps://academic.oup.com/ndt/article-pdf/38/4/894/49715295/gfac198.pdf

journalhttps://doi.org/10.1093/ndt/gfac198

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35700142

Fields of Study

Hormonal Regulation and HypertensionDiabetes Treatment and ManagementDialysis and Renal Disease Management03 medical and health sciences0302 clinical medicineHumansDiabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicClinical Trials, Phase II as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicNaphthyridinesBenzhydryl CompoundsGlucosides

MeSH Terms

Benzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NephropathiesGlucosidesHumansNaphthyridinesMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicRenal Insufficiency, Chronic

Keywords

EmpagliflozinMedicineType 2 diabetesKidney diseaseDiabetes mellitusBenzhydryl compoundsConfidence intervalInternal medicineClinical endpointIntensive care medicineRandomized controlled trialEndocrinologyDiabetesChronic Kidney DiseaseMacroalbuminuriaFinerenoneDAPAGLIFLOZIN610GLOMERULAR-FILTRATION-RATEClinical Trials, Phase II as TopicGlucosidesMedicine and Health SciencesHumansMulticenter Studies as TopicBENEFITDiabetic NephropathiesRenal InsufficiencyCOTRANSPORTER 2 INHIBITORSChronicRenal Insufficiency, ChronicNaphthyridinesRandomized Controlled Trials as TopicRECEPTORICTS (Institute of Clinical and Translational Sciences)Diabetes Mellitus, Type 2Original ArticleType 2

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

FAIR Checklist

Authors (11)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)